While combined MEK inhibition and PI3K pathway inhibition strategies have shown efficacy in PDAC, as well as other cancers [16,23,30,31,32,33,34,35], they have also faced challenges due to modest effectiveness and therapeutic toxicity [36,37,38,39]. Here, MAP2K7 is linked to cancer.